Protocol Ledger

NCT03460990 · Phase III · COMPLETED

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Interventional Phase III clinical trial protocol NCT03460990 sponsored by Vertex Pharmaceuticals in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-01 Enrollment: 116 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03460990
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)116 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03460990
Protocol FieldVerified Registry Value
NCT IdentifierNCT03460990
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment116 participants (ACTUAL)
Registered Start Date2018-05-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03460990
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MDOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI